天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04

最後更新日期：115.03

癌症類別	**HD**
淋巴癌	(A) Classical type (I) Stage ≦ II **ABVD 3-6 cycles (± R/T)** Epirubicin 30 mg/m^2 (N/S 100 c.c.; 30 mins) D1,15 Bleomycin 8 mg/m^2 (N/S 100 c.c.; 30 mins) D1,15 Oncovin 1.4 mg/m^2(max 2mg) (N/S 100 c.c.; 30 mins) D1,15 Dacarbazine 375 mg/m^2 (N/S 500 c.c.; 4 hrs) D1,15 (N Endl J Med 2010;363:640-652)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**HD**
淋巴癌	(A) Classical type (II) Stage III~IV **1.ABVD 6 cycles** Epirubicin 30 mg/m^2 (N/S 100 c.c.**;** 30 mins) D1,15 Bleomycin 8 mg/m^2 (N/S 100 c.c.**;** 30 mins) D1,15 Oncovin 1.4 mg/m^2(max 2mg) (N/S 100 c.c.**;** 30 mins) D1,15 Dacarbazine 375 mg/m^2 (N/S 500 c.c.**;** 4 hrs**)** D1,15 (J Clin Oncol 2010;28:4199-4206) (III) Stage IV(IPS Score:4-7 分；CD30+；treatment naïve) 1. BV-AVD，Q4wk*6 cycles Brentuximab vedotin 1.2mg/kg (N/S 100 c.c.; 30 mins) D1,15 Epirubicin 30mg/ m2 (N/S 100 c.c.; 30 mins) D1,15 Oncovin 1.4 mg/m2(max 2mg) (N/S 100 c.c.; 30 mins)D1,15 Dacarbazine 375 mg/m2 (N/S 500 c.c.; 4 hrs) D1,15 (NEJM 2018；378:331-344)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**HD**
淋巴癌	(B) Lymphocyte-predominant type **1.ABVD+(*Rituximab) 6-8 cycles** Epirubicin 30 mg/m^2 (N/S 100 c.c.; 30 mins) D1,15 Bleomycin 8 mg/m^2 (N/S 100 c.c.; 30 mins) D1,15 Oncovin 1.4 mg/m^2(max 2mg) (N/S 100 c.c.; 30 mins) D1,15 Dacarbazine 375 mg/m^2 (N/S 500 c.c.; 4 hrs) D1,15 *Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or *Rituximab 1400mg S.C. (Blood 2011;118:4585-4590)(Blood 2013; 122:4182-4188) **2. CHOP+ (* Rituximab)** Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Solu-medrol 125 mg 125 mg v. D1-3 *Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or *Rituximab 1400mg S.C. (ASH Annual Meeting Abstract 2010;106:2812) (Blood 2013; 122:4182-4188)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**HD**
淋巴癌	**3. .EPOCH+ (*Rituximab)** Etoposide 50 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Oncovin 0.4 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Epirubicin 14 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Solu-medrol 125 mg v. D1 ~5 (or prednisolone 60mg/ m^2 D1 ~5) Endoxan 750 mg/m^2 (N/S 300 c.c.; 2 hrs) D5 *Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6) or *Rituximab 1400mg S.C. (Annals of oncology 2004; 15(3): 511-516) **4. ***Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or *Rituximab 1400mg S.C.

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL**
淋巴癌	**(I) First-line** 1. Endoxan p.o. 50,100 mg /d or Endoxan 600mg/m^2 (N/S 300 c.c.; 2 hrs) q 4wks 2. Prednisolone 100mg/m^2 /d or Solu-medrol 125 mg/d ×5 days q 4wks 3. Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or Rituximab 1400mg S.C. 4. Obinutuzuma+chlorambucil (113/2/1 申請條件依健保給付規定 9.79) (N Engl J Med 2014;370(12):1101-1110) ● In cycle 1 ● Obiutuzumab 1000mg (N/S 500ml , ≥ 4 hrs) on D1, D8. D15(dose titrate as protocol) ● Chlorambucil 0.5mg/kg po on D1. D15 ● In Cycle 2-6 ● Obiutuzumab 1000mg (N/S 500ml , ≥ 4 hrs) on D1, ● Chlorambucil 0.5mg/kg po on D1. D15

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL**
淋巴癌	(I) First-line (Conti.) 5. CVP ● Endoxan 600 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 or 300 mg/m^2 /d p.o. D1-5 ● Oncovin 1.4 mg/ m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 ● Solu- medrpl 125 mg v. D1-D3 (Blood 2001;98:2319-2325) 6. Bendamustine 90 mg /m^2 (N/S 100 c.c.; 1 hr) D1,2 q 28 days + Rituximab 375 mg/ m^2 or rituximab 1400mg SC D1 or D4 * 6 cycles (J Clin Oncol 2014;32:1236-1241) 7. Monotherapy: Bendamustine 100 mg/ m^2 D1,D2 q 28 days * 6 cycles 8. Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-5 * 6 cycles Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D7 or Rituximab 1400mg S.C. (Blood 2003;101:6-14)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL**
淋巴癌	(I) First-line (Cont.) 9. FCR Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-3 Cyclophosphamide 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D5 or Rituximab 1400mg S.C. (Blood 2011:117:3016-3024) 10. FR（Fludarabine、Rituximab) Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-5 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D7 or Rituximab 1400mg S.C. (Blood 2003;101:6-14) 11. 單獨使用於具有 17p 缺失的慢性淋巴球性白血病(CLL)成年患者 ● Ibrutinib 560mg po QD (blood adv. 2022;6:3440-3450) ● Acalabrutinib 100mg po BID (J Clin Oncol2021; 39:344-3452) ● Zanubrutinib 160mg po BID or 320mg po QD (Lancet Oncol 2022;23:1031-1043)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL)**
淋巴癌	**(II) 2nd-line Tx (if not use in first-line)** 1. Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-5 2.FC { Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-3 { Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 (Ther Clin Risk Manag 2009; 5:187-207) 3.reduced-dose FCR { Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-3 { Cyclophosphamide 600,750 mg/m2 (N/S 300 c.c.; 2 hrs) D1 { Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D5 or Rituximab 1400mg S.C. (Leuk Res 2014.Aug; 38(8): 891-5) 4.reduced-dose FR { Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-5 { Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D7 or Rituximab 1400mg S.C. (Cancer Control 2015 Oct; 22(4): 17-23) 5. Rituximab 375mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or Rituximab 1400mg S.C. q3wks

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL**
淋巴癌	**(II) 2nd-line Tx (cont.)** **6. FCR** Fludarabine 25 mg/m^2/d (N/S 100 c.c.; 1 hr) D1-3 Cyclophosphamide 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 Rituximab 375mg/m2 (N/S 500 c.c.; ≥ 4 hrs) D5 or Rituximab 1400mg S.C. (Blood 2011:117:3016-3024) **7. R-CHOP**(with methylprednisolone) Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) Solu-medrol 125 mg 125 mg v. D1-3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. (Blood 2010;116:2040-2045) 8. R-CHOP (with prednisolone) Cyclophosphamide (600,750) mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 50 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1.4 mg/ m^2 (max 2mg) + N/S 100 cc ivd 30 mins Prednisolone 100mg/day x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C.

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**SLL/CLL**
淋巴癌	**(II) 2nd-line Tx (cont.)** 9.R-mini-CHOP (with methylprednisolone) Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Solu-medrol 125 mg ivp on D1-D3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. **10.** R-mini-CHOP (with prednisolone) Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Prednisolone 100mg/day po x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. 11. Bendamustine 100mg/ m2 D1,D2 **(monotherapy)** 12. Bendamustine 90mg/ m2 D1,D2 Rituximab 375mg/ m2 or 1400mg S.C.，D1，D2 **13. venetoclax (17p 缺失): titrate as protocol, max 400mg po QD). (J Adv. Pract. Oncol 2017; 38(6): 647-652)** 14. Acalabrutinib (非 IGHV 突變): 100mg po BID (J Clin Oncol2021; 39:344-3452) 15. Zanubrutinib (非 IGHV 突變): 160mg po BID or 320mg po QD (Lancet Oncol 2022;23:1031-1043) **(III) 3rd-line Tx** 1. Acalabrutinib (二線以上治療惡化):100mg po BID (J Clin Oncol2021; 39:344-3452) 2. Zanubrutinib (非 IGHV 突變): 160mg po BID or 320mg po QD (Lancet Oncol 2022;23:1031-1043)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Follicular Lymphoma(classic FL，gr1，2，3A；gr3B as DLBCL)**
淋巴癌	**(A) lst-line Tx** **1.R-CHOP**(with methylprednisolone) Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) Solu-medrol 125 mg 125 mg v. D1-3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. (Blood 2010;116:2040-2045) 2. R-CHOP (with prednisolone) Cyclophosphamide (600,750) mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 50 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1.4 mg/ m^2 (max 2mg) + N/S 100 cc ivd 30 mins Prednisolone 100mg/day x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. 3.R-mini-CHOP (with methylprednisolone) Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Solu-medrol 125 mg ivp on D1-D3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C.

淋巴癌	**4.** R-mini-CHOP (with prednisolone) Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Prednisolone 100mg/day po x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. **5.R-COP** Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Solu-medrol 125 mg v. D1-3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) or Rituximab 1400mg S.C. D1 or D3 (J Clin Oncol 2008;206:4579-4586) 6.Bendamustine 90mg/m2 D1，D2 Rituximab 375mg/m2 or 1400mg S.C. D1，D3 Q3wk*6 cycles (B) Extended maintenance therapy : Rituximab 375mg/m2 or 1400mg S.C. Q3M*8 cycles

淋巴癌	C) 2nd-line Tx(not including SCT) 1. Bendamustine 90 mg /m2 (N/S 100 c.c.; 1 hr) D1,2 q 28 days + Rituximab 375 mg/m2 (N/S 500 c.c.; ≥ 4 hrs) or Rituximab 1400mg S.C.* 6 cycles (Lancet 2013;381:1203-1210) 2. Monotherapy: Bendamustine 100 mg/ m2 (N/S 100 c.c.; 1 hr) D1,D2 q 28 days * 6 cycles (J Clin Oncol 2008; 26:4473-4479) 3.FR ● Fludarabine 25 mg/m2/d (N/S 100 c.c.; 1 hr) D1-5 ● Rituximab 375 mg/m2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D7 or Rituximab 1400mg S.C. (J Clin Oncol 2005;23:694-704) 4.Obinutuzumab+Bendamustin ● In cycle 1 ■ Obiutuzumab 1000mg (N/S 500ml , ≥ 4 hrs) on D1, D8. D15(dose titrate as protocol) ■ Bendamustine 90mg/m2 (N/S 100ml, 1hr) on D1. D2 ● In cycle 2 ■ Obiutuzumab 1000mg (N/S 500ml , ≥ 4 hrs) on D1 ■ Bendamustine 90mg/m2 (N/S 100ml, 1hr) on D1. D2

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Mantle cell lymphoma**
淋巴癌	**(A) lst-line Tx** **1.COP** Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Solu-medrol 125 mg v. D1-3 **2.CHOP** Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) D1 Solu-medrol 125 mg v. D1-3 *Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. (J Clin Oncol 2005;23:1984-1992) **3. Hyper CVAD A ⟷ B q4wks** **(A)** Epirubicin 50 mg/m^2 + N/S 100 cc ivd 30 mins on D4 Vincristine 1.4 mg/m2 (max 2mg) + N/S 100 cc ivd 30 mins on D4 Cyclophosphamide 300 mg/m^2 + N/S 300 cc ivd 2 hrs q12h on D1-D3 (6 doses) Mesna 600 mg/m^2+ N/S 500 cc ivd 24 hrs on D1-D3 Vincristine 1.4 mg/m^2 (max 2mg) + N/S 100 cc ivd 30 mins on D11 Dexamethasone 40 mg p.o. or v. D1-4 & D11-14

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Mantle cell lymphoma**
淋巴癌	(B) MTX 200 mg/m^2 (N/S 500 c.c.; 3hrs) D1 MTX 800 mg/m^2 (N/S 500 c.c.; 24 hrs) D1 Leucovorin 15mg gid × 10 days Ara-C 3g/m^2 (N/S 500 c.c.; 3hrs) q12h × 4 doses D2,3 (J Clin Oncol 2005;23:7013-7023) (Br J Haematol 2012;156:346-353) 4.Bendamustine 90mg/m2 D1，D2 Rituximab 375mg/m2 or 1400mg S.C. D1 or D3 (Stage III~IV 不適合移植) 5. Bortezomid-based regimen (VR-CAP) (Lancet Oncol 2018; 19: 1449-1458) Velcade 1.3mg/m2 SC on D1,4,8,11 Rituximab 375mg/m2 (N/S 500 c.c.; ≥ 4 hr) or 1400mg SC D0，D1 Epirubicin 50mg/m2 (N/S 100ml; 1 hr) on D1 Cyclophosphamide 750mg/m2 (N/S500ml;3 hrs) D1 **(B) 2-line Tx** **1. Bendamustine** 90 mg /m^2 (N/S 100 c.c.; 1 hr) D1,2 q 28 days + Rituximab 375 mg/ m^2 (N/S 500 c.c.; 4 hrs) D1 or D4 * or Rituximab 1400mg S.C.*6 cycles or Monotherapy: Bendamustine 100 mg/ m^2 D1,D2 q 28 days * 6 cycles (J Clin Oncol 2008; 26:4473-4479)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Mantle cell lymphoma**
淋巴癌	**2. R-EPOCH** Etoposide 50 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Oncovin 0.4 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Epirubicin 14 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Solu-medrol 125 mg v. D1 ~5(or prednisolone 60mg/ m^2/d on D1-D5) Endoxan 750 mg/m^2 (N/S 300 c.c.; 2 hrs) D5 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6 or Rituximab 1400mg S.C. (Annals of oncology 2004; 15(3): 511-516) **3. R- ESHAP** Etoposide 40 mg/ m^2/d (N/S 500 c.c.; 3 hrs) D1-4 Cisplatin 60 mg/m^2 (N/S 500 c.c.; 24 hrs) D4 or 25 mg/m^2/d (N/S 500 c.c./d) C.I. D1-4 Ara-C 2 g/m^2 (N/S 500 c.c.; 3hrs) D5 Solu-medrol 500 mg v. D1-5 Rituximab 375mg/m2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6 or Rituximab 1400mg S.C. (Hematologica. 2008; 93(12):1829-1836) 4. Acalabrutinib 150m po BID (Leukemia 2019; 33:2762-2766) 5. Zanubrutinib 160mg po BID or 320mg po QD (Blood Adv. 2021;5:2577-2585) 6. Bortezomib-base C/T(一線未使用) 7. Ibrutinib 560mg po QD (Blood 2015; 126:739-745)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**DLBCL**
淋巴癌	(A) lst-line Tx **1.R-CHOP(with methylprednisolone)** Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 Oncovin 1.4mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Endoxan 600,750 mg/m^2 (N/S 300 c.c.; 2 hrs) Solu-medrol 125 mg 125 mg v. D1-3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. (Blood 2010;116:2040-2045) 2. **R-CHOP (with prednisolone)** Cyclophosphamide (600,750) mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 50 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1.4 mg/ m^2 (max 2mg) + N/S 100 cc ivd 30 mins Prednisolone 100mg/day x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. 3.**R-mini-CHOP (with methylprednisolone)** Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Solu-medrol 125 mg ivp on D1-D3 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C.

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**DLBCL**
淋巴癌	**4. R-mini-CHOP (with prednisolone)** Cyclophosphamide 400 mg/ m^2 + N/S 300 cc ivd 2 hrs Epirubicin 40 mg/ m^2 + N/S 100 cc 30 mins Vincristine 1 mg + N/S 100 cc ivd 30 mins Prednisolone 100mg/day po x 5 days Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. **5.R-EPOCH** Etoposide 50 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Oncovin 0.4 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1~4 Epirubicin 14 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24hrs D1 ~4 Solu-medrol 125 mg v. D1 ~5 (or prednisolone 60mg/ m^2/d on D1-D5) Endoxan 750 mg/m^2 (N/S 300 c.c.; 2 hrs) D5 Rituximab 375 mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6 or Rituximab 1400mg S.C. (Br J Haematol 2015;169:188-198) (J Clino Oncol 2008:26:2717-2724)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**DLBCL**
淋巴癌	(B)2nd-line Tx **1. ESHAP +/- R** Etoposide 40 mg/ m^2/d (N/S 500 c.c.; 3 hrs) D1-4 Solu-medrol 500 mg v. D1-5 Cisplatin 60 mg/m^2 (N/S 500 c.c.; 24 hrs) D4 or 25 mg/m^2/d (N/S 500 c.c./d) C.I. D1-4 Ara-C 2 g/m^2 (N/S 500 c.c.; 3hrs) D5 (Rituximab 375mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6) or Rituximab 1400mg S.C. (J Clini Oncol 1994;12:1169-1176) **2. .ICE +/- R** Etoposide 100 mg/m^2 /d (N/S 500 c.c.; 3 hrs) D1-3 Ifosfamide 1.5 g/m^2/d (N/S 500 c.c. C.I). × D2-4 Mesna 1.5 g/m^2/d (N/S 500 c.c. C.I). × D2-4 Cisplatin 60mg/m^2 (N/S 500 c.c; 24hrs) D2 (Rituximab 375mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6) or Rituximab 1400mg S.C. (J Clin Oncol 2010;28:4184-4190)

癌症類別	**DLBCL**
淋巴癌	(C) 2nd-line (cont.) 1 .EPOCH (+ R) Etoposide 50 mg/ m2 /d (N/S 500 c.c./d) C.I. 96hrs D1 ~4 Oncovin 0.4 mg/ m2 /d (N/S 500 c.c./d) C.I. 96hrs D1 ~4 Epirubicin 14 mg/ m2 /d (N/S 500 c.c./d) C.I. 96hrs D1 ~4 Endoxan 750 mg/m2 (N/S 300 c.c.; 2 hrs) D5 Solu-medrol 125 mg v. D1 ~5(or prednisolone 60mg/ m2/d on D1-D5) Rituximab 375 mg/m2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6 or Rituximab 1400mg S.C. (J Clin Oncol 2000;18:3663-3642) 2.Tafasitamab 合併 Lenalidomide (Lancet Oncol 21(7):978-988.) ● In cycle 1 ■ Tafasitamab 12mg/kg on D1. 4. 8. 15. 22. ■ Lenalidmide 25mg po on D1-21 ● In C2-3 ■ Tafasitamab 12mg/kg on D1. 8. 15. 22. ■ Lenalidmide 25mg po on D1-21 ● In C4-12 ■ Tafasitamab 12mg/kg on D1. 15. ■ Lenalidmide 25mg po on D1-21 ● In C13- ■ Tafasitamab 12mg/kg on D1. 15

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**DLBCL**
淋巴癌	D) 3rd-line 1. polatuzumab vedotin-Rituximab-Bendamustine (J Clin Oncol 38(2):155-165.) ● Cycle 1 ■ polatuzumab vedotin 1.8mg/kg (N/S 500 c.c.; 4 hrs) on D1 ■ Rituximab 375 mg/ m2 (N/S 500 c.c.; 4 hrs) D2 ■ Bendamustine 90 mg /m2 (N/S 100 c.c.; 1 hr) D2,3 ● Cycle 2-6 ■ polatuzumab vedotin 1.8mg/kg (N/S 500 c.c.; 4 hrs) on D1 ■ Rituximab 375 mg/ m2 (N/S 500 c.c.; 4 hrs) D1 ■ Bendamustine 90 mg /m2 (N/S 100 c.c.; 1 hr) D1,2

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**DLBCL**
淋巴癌	D) 3rd-line (cont.) 2. Epcoritamab (J Clin Oncol 41(12):2238-2247.) ● Cycle 1: 0.16mg SC on D1, 0.8mg SC on D8. 48mg SC on D15. D21 ● Cycle 2&3: 48mg SC on D1, 8. 5, 22 ● Cycle 4-9: 48mg SC on D1. 15 ● Cycle 10-: 48mg SC on D1 3. Obinutuzumab – Glofitamab (Lancet Oncol (2016); 17(8): 1081-1093) ● Cycle 1 ■ Obinutuzumab 1000mg D1 (500ml . > 4hrs) ■ Glofitamab 2.5mg D8 (250ml, >4 hrs); 10mg D10 (500ml., > 4hrs) ● Cycle 2-12 ■ Glofitamab 30mg D1 (500ml; >4hrs)

天主教聖馬爾定醫院
Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Burkitt's Lymphoma**
淋巴癌	**Low-risk** **(1) CODOX-M(may add I.T. in each cycle)** Endoxan 1200 mg/ m^2 (N/S 500 c.c.; 6 hrs) D1 Oncovin 1.4 mg/m^2 (max.2mg) (N/S 100 c.c.; 30 mins) D1 Epirubicin 50 mg/m^2 (N/S 100 c.c.; 30 mins) D1 High-dose MTX 300 mg/m^2 (500 c.c.; 6hrs) → D10 60 mg/m^2 (N/S 100 c.c.;1 hr) 38hrs later, 60 mg/m^2 I.V. 1hr D11 Solu-medrol 125 mg v. D1-2 Rituximab(optioal) 375mg/m2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D3 or Rituximab 1400mg S.C. May be considered I.T. MTX (A) 12mg D10, cycle 1-6 (B)12.5mg D3, cycle 2-3 (Cancer 2003;98:1196-1205) **(2)** Hyper CVAD A ⟷ B q4wks**(may add I.T. in each cycle)** **(A)** Epirubicin 50 mg/m^2 + N/S 100 cc ivd 30 mins on D4 Vincristine 1.4 mg/m2 (max 2mg) + N/S 100 cc ivd 30 mins on D4 Cyclophosphamide 300 mg/m^2 + N/S 300 cc ivd 2 hrs q12h on D1-D3 (6 doses) Mesna 600 mg/m^2+ N/S 500 cc ivd 24 hrs on D1-D3 Vincristine 1.4 mg/m^2 (max 2mg) + N/S 100 cc ivd 30 mins on D11 Dexamethasone 40 mg p.o. or v. D1-4 & D11-14 (B) MTX 200 mg/m^2 (N/S 500 c.c.; 3hrs) MTX 800 mg/m^2 (N/S 500 c.c.; 24 hrs) D1 Leucovorin 15mg gid × 10 days Ara-C 3000mg/m^2 (N/S 500 c.c.; 3hrs) q12h × 4 doses D2,3 (Cancer 2006;106:1569-1580) (3)I.T. MTX (A) 12mg on D2 Cytarabine 100mg on D8

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Burkitt's Lymphoma**
淋巴癌	**(3)EPOCH(+R)** Etoposide 50 mg/ m^2 /d (N/S 500 c.c./d) C.I. 96 hrs D1 ~4 Oncovin 0.4 mg/ m^2 /d (N/S 500 c.c./d) C.I. 96 hrs D1 ~4 Epirubicin 14 mg/ m^2 /d (N/S 500 c.c./d) C.I. 96 hrs D1 ~4 or 40 mg/ m^2 (N/S 100 c.c.; 30 mins) D1 Solu-medrol 125 mg v. D1 ~5(or prednisolone 60mg/ m^2/d on D1-D5) Endoxan 750 mg/m^2 (N/S 300 c.c.; 2 hrs) D5 (Rituximab 375mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6) or Rituximab 1400mg S.C. May be considered I.T. MTX 12 mg D2; Ara-C 100 mg D8 (Cancer 2012; 118:3977-3983)

天主教聖馬爾定醫院

Chemotherapy Regimes

最初出版日期：99.04
最後更新日期：115.03

癌症類別	**Burkitt's Lymphoma**
淋巴癌	**High-risk** **1.**Hyper CVAD A ⟷ B **(A)** Epirubicin 50 mg/m^2 + N/S 100 cc ivd 30 mins on D4 Vincristine 1.4 mg/m2 (max 2mg) + N/S 100 cc ivd 30 mins on D4 Cyclophosphamide 300 mg/m^2 + N/S 300 cc ivd 2 hrs q12h on D1-D3 (6 doses) Mesna 600 mg/m^2+ N/S 500 cc ivd 24 hrs on D1-D3 Vincristine 1.4 mg/m^2 (max 2mg) + N/S 100 cc ivd 30 mins on D11 Dexamethasone 40 mg p.o. or v. D1-4 & D11-14 (B) MTX 200 mg/m^2 (N/S 500 c.c.; 3hrs) MTX 800 mg/m^2 (N/S 500 c.c.; 24 hrs) D1 Leucovorin 15mg gid × 10 days Ara-C 3000mg/m^2 (N/S 500 c.c.; 3hrs) q12h × 4 doses D2,3 (Cancer 2006;106:1569-1580) May be considered I.T. MTX 12 mg D2; Ara-C 100 mg D8 (Cancer 2006;106:1569-1580)
淋巴癌	**2.EPOCH (for poor performance)** Etoposide 50 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24 hrs D1 ~4 Oncovin 0.4 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24 hrs D1 ~4 Epirubicin 14 mg/ m^2 /d (N/S 500 c.c./d) C.I. 24 hrs D1 ~4 Solu-medrol 125 mg v. D1 ~5(or prednisolone 60mg/ m^2/d on D1-D5) Endoxan 750 mg/m^2 (N/S 300 c.c.; 2 hrs) D5 (Rituximab 375mg/m^2 (N/S 500 c.c.; ≥ 4 hrs) D1 or D6) or Rituximab 1400mg S.C. (Cancer 2012; 118:3977-3983)